Lifestyle Intervention for Pregnancy Weight Gain
Trial Summary
What is the purpose of this trial?
The aim of this trial is to investigate the effectiveness of a mobile health (mhealth) intervention to help overweight and obese women achieve appropriate gestational weight gain (GWG) for their pre-pregnancy body mass index (BMI). The goal of the intervention is to help women achieve GWG within the range recommended by the Institute of Medicine. The investigators propose an adaptive intervention that begins with an effective, yet low resource-intensive treatment and then provides incremental support and resources only to patients who need them. The intervention includes: 1) an mHealth tool allowing data to be automatically transmitted to a mobile website; 2) personalized text messages; and 3) personalized 1:1 telephone coaching sessions. The latter more intensive components are reserved for patients whose GWG is not within the IOM guidelines. The lifestyle intervention will be delivered through 1 telephone counseling session with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and weekly e-mails of core lifestyle intervention sessions. Personalized text messages and 1:1 telephone coaching sessions will be given to those who are not meeting the GWG guidelines. The lifestyle intervention will be compared to usual medical care. Maternal outcomes will be assessed shortly before delivery and at 6 weeks postpartum. Infant birthweight and weight at one year will also be assessed.
Research Team
Eligibility Criteria
This trial is for overweight or obese pregnant women with a pre-pregnancy BMI of 25 to <40, who are patients at Kaiser Permanente in San Francisco or Oakland. Participants must have access to a smartphone and Wi-Fi, understand English, and not be on bed rest or planning to move during the study.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Lifestyle Intervention (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kaiser Permanente
Lead Sponsor
Greg A. Adams
Kaiser Permanente
Chief Executive Officer since 2019
MBA from University of Southern California
Dr. Edward M. Ellison
Kaiser Permanente
Chief Medical Officer since 2015
MD from Harvard Medical School
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Dr. Griffin P. Rodgers
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chief Executive Officer since 2007
MD, M.A.C.P.
Dr. Griffin P. Rodgers
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chief Medical Officer since 2007
MD, M.A.C.P.